Market Trends of Global Hypertrophic Cardiomyopathy Therapeutics Industry
This section covers the major market trends shaping the Hypertrophic Cardiomyopathy Therapeutics Market according to our research experts:
Beta-Adrenergic Blocking Agents Segment is Expected to Witness Growth Over the Forecast Period
Beta-blockers function by obstructing the actions of the hormone epinephrine and referred to as adrenaline. Beta-blockers reduce blood pressure by causing the heart to beat more gradually and gently. Beta-adrenergic blockers (β-blockers) are an important class of drugs that are primarily prescribed by cardiologists for the treatment of various heart diseases including thickened heart muscle (hypertrophic cardiomyopathy (HCM)), among others. Thus, owing to the efficacy of the beta-blockers for the treatment of HCM is predicted to fuel the segment growth over the analysis period.
Various research shows that beta-adrenergic blockers prevent catecholamines from binding to the receptor sites which results in a decrease in heart rate, heart contraction, and blood pressure. This shows the effects of beta-adrenergic blockers on the heart, lungs, and blood vessels. In addition, the article 'Beta-Blockers and Exercise Hemodynamics in Hypertrophic Cardiomyopathy' published in April 2022 stated that, despite a lack of trial evidence, beta-blockers have long been regarded as a first-line treatment for HCM. Therefore, the adoption of Beta-Adrenergic Blocking Agents or beta-blockers for the treatment of HCM is expected to boost segment growth.
Moreover, the recent developments and clinical trials in the segment are increasing recently. For instance, in August 2022, a clinical trial was registered titled 'A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM) (DISCOVER-HCM)' with the objective to evaluate the safety of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) treated in the real-world setting. The patients of the trial will be given beta-blocker (BB)/non-dihydropyridine(non-DHP) calcium channel blocker (CCB)/disopyramide as prescribed by a physician. Such advancements in the segment are expected to fuel segment growth.
Therefore, owing to the factors mentioned above, the segment is anticipated to witness growth over the forecast period.
North America is Expected to Dominate the Market and Expected to do Same in the Forecast Period
North America is anticipated to witness growth over the forecast period and dominate the market. Among other countries in the region, the United States is leading the market, due to factors such as an increase in healthcare expenditure, increasing research and developments, and a rising prevalence of various communicable or non-communicable diseases. Additionally, the rising geriatric population across the United States is the primary driver for the United States syndromic multiplex diagnostic market.
For instance, as per the data submitted in the article 'Stable Rates of Obstructive Hypertrophic Cardiomyopathy in a Contemporary Era' published in January 2022, hypertrophic cardiomyopathy is the most prevalent type of inherited hereditary heart disease and, the prevalence of HCM in the United States is estimated to be 1 in 500 persons, yet a sizable portion of patients go undiagnosed. Thus, such a high burden of the disease is demanding therapeutics for the treatment and patient survival. Therefore, it is expected to propel the studied market growth in the region over the forecast period.
Moreover, the development activities by the market players in the form of product launches, acquisitions, mergers, and investments are also expected to enhance the market growth. For example, in October 2021, MyoKardia, Inc. registered a Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM).
In addition, in February 2022, Cytokinetics, Incorporated opened enrollment for SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), a Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Aficamten is a next-generation cardiac myosin inhibitor in development for the potential treatment of HCM. SEQUOIA-HCM builds on the positive results from REDWOOD-HCM, a Phase 2 clinical trial of aficamten, that demonstrated that treatment with aficamten for 10 weeks resulted in reductions from baseline compared to placebo in the average resting left ventricular outflow tract pressure gradient (LVOT-G) and the average post-Valsalva LVOT-G, with no treatment interruptions or discontinuations, nor any treatment-related serious adverse events. Thus, these increasing developments in the market across all the countries in North America are anticipated to drive market growth over the forecast period in the country.
Therefore, owing to the factors mentioned above, North America is predicted to be the major market for syndromic multiplex diagnostics, which is expected to witness growth over the forecast period.
